IGM Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . IGM Biosciences
IGMS Stock  USD 1.21  0.02  1.63%   
IGM Biosciences financial statements provide useful quarterly and yearly information to potential IGM Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on IGM Biosciences financial statements helps investors assess IGM Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting IGM Biosciences' valuation are summarized below:
Gross Profit
-152.5 M
Market Capitalization
73.5 M
Enterprise Value Revenue
277.3705
Revenue
2.7 M
Earnings Share
(3.24)
There are over one hundred nineteen available fundamental trends for IGM Biosciences, which can be analyzed over time and compared to other ratios. All traders should confirm IGM Biosciences' regular fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 557.2 M in 2025. Enterprise Value is likely to gain to about 508.7 M in 2025

IGM Biosciences Total Revenue

2.81 Million

Check IGM Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IGM Biosciences' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 10 M or Interest Expense of 8.3 M, as well as many indicators such as Price To Sales Ratio of 131, Dividend Yield of 0.0 or PTB Ratio of 8.06. IGM financial statements analysis is a perfect complement when working with IGM Biosciences Valuation or Volatility modules.
  
Check out the analysis of IGM Biosciences Correlation against competitors.
For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.

IGM Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets299.2 M265.7 M155.3 M
Slightly volatile
Other Current Liabilities15.1 M26.9 M8.1 M
Slightly volatile
Total Current Liabilities25.9 M37.6 M13.8 M
Slightly volatile
Property Plant And Equipment Net45.3 M71 M23.7 M
Slightly volatile
Accounts Payable933.9 K983 K1.5 M
Slightly volatile
Cash25.2 M26.5 M43.8 M
Slightly volatile
Non Current Assets Total47.9 M72.1 M25.1 M
Slightly volatile
Non Currrent Assets Other944.8 K1.1 M513.9 K
Slightly volatile
Other Assets2.4 M2.3 M695.9 K
Slightly volatile
Cash And Short Term Investments245.2 M183.8 M127 M
Slightly volatile
Common Stock Total Equity210.3 K373.8 K138.6 K
Slightly volatile
Common Stock Shares Outstanding31.4 M60.5 M16.4 M
Slightly volatile
Non Current Liabilities Total94.6 M179.9 M66.8 M
Slightly volatile
Capital Surpluse722.5 M688.1 M275.5 M
Slightly volatile
Other Current Assets10.1 M9.8 M5.3 M
Slightly volatile
Total Liabilities120.6 M217.5 M80.7 M
Slightly volatile
Property Plant And Equipment Gross54.8 M100.3 M28.6 M
Slightly volatile
Total Current Assets251.3 M193.6 M130.2 M
Slightly volatile
Common Stock283.2 K342 K148.2 K
Slightly volatile
Property Plant Equipment88.2 M84 M25.4 M
Slightly volatile
Short and Long Term Debt Total29.5 M45.2 M16.1 M
Slightly volatile
Current Deferred Revenue2.5 M2.7 M39.9 M
Slightly volatile
Net Receivables966 K920 K339.8 K
Slightly volatile
Capital Stock403.1 K596 K187.5 K
Slightly volatile

IGM Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10 M9.5 M2.6 M
Slightly volatile
Selling General Administrative30.6 M50.4 M16.9 M
Slightly volatile
Other Operating Expenses142 M211.3 M78.3 M
Slightly volatile
Research Development111.5 M160.9 M61.4 M
Slightly volatile
Cost Of Revenue8 M7.4 M7.3 M
Slightly volatile
Total Operating Expenses142 M211.3 M78.3 M
Slightly volatile
Reconciled Depreciation9.6 M9.1 M2.5 M
Slightly volatile
Total Other Income Expense Net13.4 M12.8 M3.4 M
Slightly volatile
Net Interest Income8.5 M12.8 M4.2 M
Slightly volatile
Interest Income8.5 M12.8 M4.2 M
Slightly volatile

IGM Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation22.7 M38.3 M11.8 M
Slightly volatile
Begin Period Cash Flow89.6 M113.1 M47.7 M
Slightly volatile
Depreciation9.6 M9.1 M2.5 M
Slightly volatile
Capital Expenditures8.6 M5.9 M4.6 M
Slightly volatile
Total Cash From Financing Activities2.3 M2.4 M57.8 M
Slightly volatile
End Period Cash Flow25.3 M26.7 M44 M
Slightly volatile
Change To Netincome65.2 M62.1 M17.2 M
Slightly volatile
Other Non Cash Items4 M2.5 M1.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio131138567
Slightly volatile
Stock Based Compensation To Revenue13.5714.283737.0888
Slightly volatile
Capex To Depreciation0.610.64223.146
Very volatile
EV To Sales138145505
Slightly volatile
Payables Turnover5.95.621.9995
Slightly volatile
Sales General And Administrative To Revenue32.5818.814942.4836
Slightly volatile
Research And Ddevelopement To Revenue57.0460.0426150
Slightly volatile
Capex To Revenue2.082.18448.3869
Slightly volatile
Cash Per Share2.893.03714.9127
Slightly volatile
Days Payables Outstanding63.8867.25383
Slightly volatile
Income Quality0.830.78140.8389
Slightly volatile
Current Ratio8.045.14435.8234
Slightly volatile
Capex Per Share0.09190.09670.6705
Slightly volatile
Revenue Per Share0.02950.04430.0281
Slightly volatile
Interest Debt Per Share0.710.74676.8371
Slightly volatile
Debt To Assets0.290.17010.7618
Slightly volatile
Days Of Payables Outstanding63.8867.25383
Slightly volatile
Ebt Per Ebit1.070.93870.9866
Very volatile
Long Term Debt To Capitalization0.350.40.4331
Slightly volatile
Quick Ratio8.185.14435.9165
Slightly volatile
Net Income Per E B T0.780.90.9671
Slightly volatile
Cash Ratio0.670.70392.0823
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.031.03821.1645
Slightly volatile
Fixed Asset Turnover0.02160.03770.0174
Slightly volatile
Debt Ratio0.290.17010.7618
Slightly volatile
Price Sales Ratio131138567
Slightly volatile
Asset Turnover0.01060.01010.0033
Slightly volatile

IGM Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap557.2 M369.7 M387.8 M
Slightly volatile
Enterprise Value508.7 M388.4 M354.2 M
Slightly volatile

IGM Fundamental Market Drivers

Cash And Short Term Investments183.8 M

IGM Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About IGM Biosciences Financial Statements

IGM Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although IGM Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in IGM Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on IGM Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 M2.5 M
Total Revenue2.7 M2.8 M
Cost Of Revenue7.4 M8 M
Stock Based Compensation To Revenue 14.28  13.57 
Sales General And Administrative To Revenue 18.81  32.58 
Research And Ddevelopement To Revenue 60.04  57.04 
Capex To Revenue 2.18  2.08 
Revenue Per Share 0.04  0.03 
Ebit Per Revenue(77.86)(81.75)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY